ReviewBone marrow transplantation2020
MicroRNAs in graft-versus-host disease: a review of the latest data.
Review in Bone marrow transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches.Frontiers in immunology · 2026Review
- Clinical Significance of microRNAs in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation.Cancers · 2023Review
- MicroRNA serum profiles and chronic graft-versus-host disease.Blood advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Detectable in biopsies and body fluids, the measurement of a single or panels of microRNAs have been reported to be quite sensitive and specific for the prediction, diagnosis, and prognosis of many diseases. Interest in the use of microRNAs as biomarkers and eventual therapeutic targets has increased exponentially in the last decade. However, in the field of graft-versus-host disease (GVHD), the discovery of their involvement in biological processes and their predictive value is only emerging. With 30-75% of patients developing GVHD following allogeneic hematopoietic cell transplant and the absence of routinely used predictive biomarkers, microRNAs are promising for early detection and follow-up of this condition. We aim to summarize the current knowledge on the involvement of these small RNAs in the pathophysiology of this disease. We also review studies investigating the potential of miRNAs as biomarkers for early detection, follow-up, and prognosis of GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.